CB-401 (Cantabio Pharmaceuticals)

N/A

Report date: 2024/01/26 17:43:00
NME

Base Information

Drug NameCB-401 (Cantabio Pharmaceuticals)
Drug Alias NameCB401 (Cantabio Pharmaceuticals)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionParkinson disease protein 7 modulators
TargetsParkinson disease protein 7
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesElan PharmaceuticalsNovAliX SASUniversity Of Cambridge +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesCantabio Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A